Physician profile
David Jarava
NPI 1295261253
$2,005.83
in general payments reported to CMS, 2019-2025
16 companies · $536 in 2025
The $536 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2023: $518 · 2024: $814 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.36 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $468.59 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $257.84 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $138.44 | 2022 | |
| Celgene Corporation | $99.90 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.56 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $73.55 | 2024 | Voquezna |
| Enterra Medical, INC. | $62.07 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $56.63 | 2024 | Iqirvo |
| Janssen Biotech, INC. | $49.39 | 2024-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $44.19 | 2023 | Rebyota |
| Boston Scientific Corporation | $27.66 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $27.48 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $22.42 | 2023 | Ocaliva |
| Novo Nordisk INC | $19.38 | 2025 | Wegovy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18.37 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jarava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.